Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Eprosartan | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Eprosartan | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Eprosartan | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Eprosartan | hsa00071 | Fatty acid degradation | 4.66E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | Eprosartan | hsa00220 | Arginine biosynthesis | 2.86E-02 | 2 | P15104, P05089 | GLUL, ARG1 | More | | Eprosartan | hsa00310 | Lysine degradation | 2.59E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | | Eprosartan | hsa00500 | Starch and sucrose metabolism | 9.77E-06 | 4 | O43451, P46976, P35573, P06737 | MGAM, GYG1, AGL, PYGL | More | | Eprosartan | hsa00512 | Mucin type O-glycan biosynthesis | 4.86E-02 | 2 | O95395, Q9NY28 | GCNT3, GALNT8 | More | | Eprosartan | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Eprosartan | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Eprosartan | hsa00591 | Linoleic acid metabolism | 1.29E-03 | 1 | P11712 | CYP2C9 | More | | Eprosartan | hsa00630 | Glyoxylate and dicarboxylate metabolism | 9.21E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | Eprosartan | hsa00730 | Thiamine metabolism | 7.19E-04 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Eprosartan | hsa00770 | Pantothenate and CoA biosynthesis | 7.90E-03 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | Eprosartan | hsa00970 | Aminoacyl-tRNA biosynthesis | 1.58E-04 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Eprosartan | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Eprosartan | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Eprosartan | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | | Eprosartan | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Eprosartan | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Eprosartan | hsa01240 | Biosynthesis of cofactors | 2.95E-02 | 2 | P13716, P14618 | ALAD, PKM2 | More | | Eprosartan | hsa01524 | Platinum drug resistance | 1.13E-02 | 5 | P10415, Q13489, P78417, P23025, P43246 | BCL2, BIRC3, GSTO1, XPA, MSH2 | More | | Eprosartan | hsa02010 | ABC transporters | 2.17E-03 | 1 | Q8IZY2 | ABCA7 | More | | Eprosartan | hsa03008 | Ribosome biogenesis in eukaryotes | 2.60E-03 | 5 | Q9NYH9, P78345, Q9BVP2, O15381, Q9GZY0 | UTP6, RPP38, GNL3, NVL, NXF2; NXF2B | More | | Eprosartan | hsa03010 | Ribosome | 5.85E-04 | 8 | P62753, P25398, P32969, P46776, P62899, P18077, P61927, P36578 | RPS6, RPS12, RPL9, RPL27A, RPL31, RPL35A, RPL37, RPL4 | More | | Eprosartan | hsa03013 | RNA transport | 2.78E-05 | 17 | O14980, P52298, Q09161, O14893, P61326, Q15287, Q7Z3B4, P35658, P68104, Q14152, O15371, O75822, P78345, P11940, Q14240, Q9Y6A5, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, RNPS1, NUP54, NUP214, EEF1A1, EIF3A, EIF3D, EIF3J, RPP38, PABPC1, EIF4A2, TACC3, FXR1 | More | | Eprosartan | hsa03020 | RNA polymerase | 4.40E-02 | 2 | P24928, P62487 | POLR2A, POLR2G | More | | Eprosartan | hsa03040 | Spliceosome | 2.00E-04 | 10 | Q14562, O43143, O60508, Q99633, Q13595, Q07955, Q01130, Q13243, Q9UMS4, P11142 | DHX8, DHX15, CDC40, PRPF18, TRA2A, SFRS1, SFRS2, SFRS5, PRPF19, HSPA8 | More | | Eprosartan | hsa03410 | Base excision repair | 7.59E-03 | 1 | P27695 | APEX1 | More | | Eprosartan | hsa04014 | Ras signaling pathway | 8.66E-03 | 7 | Q9NRA1, Q13009, P0DP23, P62873, P63218, P50151, P19174 | PDGFC, TIAM1, CALM1, GNB1, GNG5, GNG10, PLCG1 | More | | Eprosartan | hsa04015 | Rap1 signaling pathway | 1.58E-02 | 6 | P20827, P49767, P63261, P25116, P0DP23, P17252 | EFNA1, VEGFC, ACTG1, F2R, CALM1, PRKCA | More | | Eprosartan | hsa04020 | Calcium signaling pathway | 1.16E-03 | 7 | Q16566, P17252, O15399, P25116, P0DP23, P23634, P49767 | CAMK4, PRKCA, GRIN2D, F2R, CALM1, ATP2B4, VEGFC | More | | Eprosartan | hsa04022 | cGMP-PKG signaling pathway | 2.55E-02 | 4 | P18848, Q8WYR1, P05141, P0DP24 | ATF4, PIK3R5, SLC25A5, CALM2 | More | | Eprosartan | hsa04024 | cAMP signaling pathway | 2.84E-02 | 5 | P0DP23, P23634, Q16566, O15399, P25116 | CALM1, ATP2B4, CAMK4, GRIN2D, F2R | More | | Eprosartan | hsa04060 | Cytokine-cytokine receptor interaction | 9.80E-04 | 16 | P27930, P14778, P26842, Q9UHF4, Q13651, P16871, P25024, Q9UBD3, P47992, P02775, P09341, P32248, P51684, P18510, P09603, P01730 | IL1R2, IL1R1, CD27, IL20RA, IL10RA, IL7R, CXCR1, XCL2, XCL1, PPBP, CXCL1, CCR7, CCR6, IL1RN, CSF1, CD4 | More | | Eprosartan | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 2.08E-04 | 11 | P51684, P32248, P09341, P19875, P25024, P02775, P25025, P47992, Q9UBD3, P14784, Q9UHF4 | CCR6, CCR7, CXCL1, CXCL2, CXCR1, PPBP, CXCR2, XCL1, XCL2, IL2RB, IL20RA | More | | Eprosartan | hsa04062 | Chemokine signaling pathway | 1.80E-06 | 19 | P25024, P25025, P09341, P19875, P47992, Q9UBD3, P07948, P42338, P19174, P62873, P63218, P50151, P49407, Q08881, Q13009, P14598, P42224, P25963, P49841 | CXCR1, CXCR2, CXCL1, CXCL2, XCL1, XCL2, LYN, PIK3CB, PLCG1, GNB1, GNG5, GNG10, ARRB1, ITK, TIAM1, NCF1, STAT1, NFKBIA, GSK3B | More | | Eprosartan | hsa04064 | NF-kappa B signaling pathway | 3.08E-03 | 13 | P10415, P51617, Q13546, P14778, P19174, Q04759, Q9UDY8, Q13077, P06239, P24522, P09341, P19875, Q06643 | BCL2, IRAK1, RIPK1, IL1R1, PLCG1, PRKCQ, MALT1, TRAF1, LCK, GADD45A, CXCL1, CXCL2, LTB | More | | Eprosartan | hsa04066 | HIF-1 signaling pathway | 3.40E-02 | 3 | Q09472, P07195, P10415 | EP300, LDHB, BCL2 | More | | Eprosartan | hsa04068 | FoxO signaling pathway | 3.52E-02 | 1 | Q96BR1 | SGK3 | More | | Eprosartan | hsa04070 | Phosphatidylinositol signaling system | 3.02E-03 | 7 | P19174, P0DP23, Q14643, P23743, O14732, P27987, P17252 | PLCG1, CALM1, ITPR1, DGKA, IMPA2, ITPKB, PRKCA | More | | Eprosartan | hsa04071 | Sphingolipid signaling pathway | 8.74E-08 | 11 | P17252, P21453, Q9H228, P01375, Q13362, Q16537, Q9BX95, Q16539, P04637, P10415, Q9UQC2 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, PPP2R5E, SGPP1, MAPK14, TP53, BCL2, GAB2 | More | | Eprosartan | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Eprosartan | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | Eprosartan | hsa04110 | Cell cycle | 2.06E-02 | 6 | Q9UJX4, O60566, Q09472, P24522, P04637, P49918 | ANAPC5, BUB1B, EP300, GADD45A, TP53, CDKN1C | More | | Eprosartan | hsa04141 | Protein processing in endoplasmic reticulum | 4.66E-04 | 11 | P18848, Q12933, P30101, Q15436, P60604, Q99941, P11142, P07900, P08238, Q9H173, Q9UNL2 | ATF4, TRAF2, PDIA3, SEC23A, UBE2G2, CREBL1, HSPA8, HSP90AA1, HSP90AB1, SIL1, SSR3 | More | | Eprosartan | hsa04145 | Phagosome | 2.54E-05 | 14 | O75015, P11215, P63261, Q15080, P14598, Q71U36, Q13509, P68371, Q13488, P05164, O60603, P35443, P27824, P13765 | FCGR3B, ITGAM, ACTG1, NCF4, NCF1, TUBA1A, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, CANX, HLA-DOB | More | | Eprosartan | hsa04151 | PI3K-Akt signaling pathway | 6.85E-05 | 11 | P62753, O43521, P27348, P07900, Q8WYR1, Q16363, P22105, Q99941, P18848, O00141, Q6ZUJ8 | RPS6, BCL2L11, YWHAQ, HSP90AA1, PIK3R5, LAMA4, TNXB, CREBL1, ATF4, SGK, PIK3AP1 | More | | Eprosartan | hsa04210 | Apoptosis | 3.78E-05 | 14 | P04637, P10415, O76075, P01375, Q9NR28, O75460, P24522, Q16548, Q13077, O43521, P43234, Q9UBR2, P18848, Q14643 | TP53, BCL2, DFFB, TNF, DIABLO, ERN1, GADD45A, BCL2A1, TRAF1, BCL2L11, CTSO, CTSZ, ATF4, ITPR1 | More | | Eprosartan | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Eprosartan | hsa04217 | Necroptosis | 2.72E-04 | 8 | Q12933, P07900, P15104, P05141, P01584, P0C0S5, Q13557, Q9H444 | TRAF2, HSP90AA1, GLUL, SLC25A5, IL1B, H2AFZ, CAMK2D, CHMP4B | More | | Eprosartan | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.85E-03 | 9 | P07550, P22694, P18848, Q13362, Q16537, P0DP23, P17252, P10415, P20020 | ADRB2, PRKACB, ATF4, PPP2R5C, PPP2R5E, CALM1, PRKCA, BCL2, ATP2B1 | More | | Eprosartan | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | | Eprosartan | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | Eprosartan | hsa04371 | Apelin signaling pathway | 7.95E-04 | 7 | P62873, P63218, P50151, Q13370, Q14344, P84022, P0DP23 | GNB1, GNG5, GNG10, PDE3B, GNA13, SMAD3, CALM1 | More | | Eprosartan | hsa04390 | Hippo signaling pathway | 1.47E-02 | 5 | P63261, Q13485, Q9UJU2, O43623, Q13489 | ACTG1, SMAD4, LEF1, SNAI2, BIRC3 | More | | Eprosartan | hsa04510 | Focal adhesion | 3.21E-02 | 6 | Q15942, P17252, Q13489, P10415, P49767, P63261 | ZYX, PRKCA, BIRC3, BCL2, VEGFC, ACTG1 | More | | Eprosartan | hsa04512 | ECM-receptor interaction | 1.90E-02 | 2 | P26012, P16070 | ITGB8, CD44 | More | | Eprosartan | hsa04520 | Adherens junction | 3.36E-02 | 4 | Q13485, Q9UJU2, O43623, P63261 | SMAD4, LEF1, SNAI2, ACTG1 | More | | Eprosartan | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Eprosartan | hsa04540 | Gap junction | 1.30E-03 | 5 | P17252, Q13509, P68371, Q71U36, Q9NRA1 | PRKCA, TUBB3, TUBB2C, TUBA1A, PDGFC | More | | Eprosartan | hsa04610 | Complement and coagulation cascades | 4.27E-06 | 1 | P0C0L4 | C4A | More | | Eprosartan | hsa04612 | Antigen processing and presentation | 9.45E-05 | 9 | P13765, P48382, Q14953, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KIR2DS5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Eprosartan | hsa04613 | Neutrophil extracellular trap formation | 7.63E-06 | 20 | P17252, P11215, O60603, P05164, P08246, Q9UM07, Q92769, Q6FI13, Q93077, P62807, P33778, O60814, P68431, P14598, Q15080, O75015, P21730, P21462, O43315, Q16539 | PRKCA, ITGAM, TLR2, MPO, ELA2, PADI4, HDAC2, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC3, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Eprosartan | hsa04614 | Renin-angiotensin system | 1.52E-02 | 1 | P50052 | AGTR2 | More | | Eprosartan | hsa04623 | Cytosolic DNA-sensing pathway | 2.59E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Eprosartan | hsa04640 | Hematopoietic cell lineage | 3.09E-04 | 10 | P13612, P14778, P27930, P11215, P25063, P07766, P01732, P01730, P09564, P09603 | ITGA4, IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD4, CD7, CSF1 | More | | Eprosartan | hsa04650 | Natural killer cell mediated cytotoxicity | 2.53E-09 | 14 | P19174, P01375, P78314, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, O75015, P26717, Q14953, P26715 | PLCG1, TNF, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | Q13547 | HDAC1 | Histone deacetylase 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.786 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.807 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | Q13547 | HDAC1 | Histone deacetylase 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.772 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | Q13547 | HDAC1 | Histone deacetylase 1 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.735 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 |
| Eprosartan | hsa04657 | IL-17 signaling pathway | 2.40E-04 | 7 | P07900, Q12933, P49841, P19875, P14780, P80188, P01375 | HSP90AA1, TRAF2, GSK3B, CXCL2, MMP9, LCN2, TNF | More | | Eprosartan | hsa04658 | Th1 and Th2 cell differentiation | 3.52E-06 | 9 | Q04759, P07766, P20963, P19174, P01730, P06239, Q9UL17, P14784, Q13761 | PRKCQ, CD3E, CD247, PLCG1, CD4, LCK, TBX21, IL2RB, RUNX3 | More | | Eprosartan | hsa04659 | Th17 cell differentiation | 2.35E-06 | 13 | P25963, Q04759, P19174, P01730, P06239, P42224, P14784, P14778, Q9UL17, P84022, P08238, P07766, P20963 | NFKBIA, PRKCQ, PLCG1, CD4, LCK, STAT1, IL2RB, IL1R1, TBX21, SMAD3, HSP90AB1, CD3E, CD247 | More | | Eprosartan | hsa04660 | T cell receptor signaling pathway | 2.21E-05 | 14 | P01375, Q04759, P42338, O95267, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, PIK3CB, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Eprosartan | hsa04664 | Fc epsilon RI signaling pathway | 6.97E-03 | 4 | P04141, P07948, P19174, P09917 | CSF2, LYN, PLCG1, ALOX5 | More | | Eprosartan | hsa04666 | Fc gamma R-mediated phagocytosis | 2.22E-02 | 4 | P49006, P06396, P14598, P17252 | MARCKSL1, GSN, NCF1, PRKCA | More | | Eprosartan | hsa04668 | TNF signaling pathway | 1.46E-04 | 8 | P01375, Q12933, Q99941, P18848, P19875, P01584, P14780, P20333 | TNF, TRAF2, CREBL1, ATF4, CXCL2, IL1B, MMP9, TNFRSF1B | More | | Eprosartan | hsa04713 | Circadian entrainment | 2.18E-02 | 4 | P0DP23, P62873, P63218, P50151 | CALM1, GNB1, GNG5, GNG10 | More | | Eprosartan | hsa04720 | Long-term potentiation | 3.70E-04 | 5 | P17252, Q16566, P0DP23, O15399, Q14643 | PRKCA, CAMK4, CALM1, GRIN2D, ITPR1 | More | | Eprosartan | hsa04723 | Retrograde endocannabinoid signaling | 1.75E-02 | 5 | Q14643, P17252, P22694, Q16539, Q16718 | ITPR1, PRKCA, PRKACB, MAPK14, NDUFA5 | More | | Eprosartan | hsa04724 | Glutamatergic synapse | 1.18E-04 | 6 | P48058, P43003, P62873, P63218, P50151, P15104 | GRIA4, SLC1A3, GNB1, GNG5, GNG10, GLUL | More | | Eprosartan | hsa04726 | Serotonergic synapse | 3.80E-02 | 4 | P62873, P63218, P50151, P09917 | GNB1, GNG5, GNG10, ALOX5 | More | | Eprosartan | hsa04727 | GABAergic synapse | 4.36E-04 | 4 | P62873, P63218, P50151, P15104 | GNB1, GNG5, GNG10, GLUL | More | | Eprosartan | hsa04728 | Dopaminergic synapse | 3.73E-03 | 9 | P14416, P63218, P50151, P49841, Q99941, P18848, Q16539, Q13557, P49407 | DRD2, GNG5, GNG10, GSK3B, CREBL1, ATF4, MAPK14, CAMK2D, ARRB1 | More | | Eprosartan | hsa04730 | Long-term depression | 4.86E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | | Eprosartan | hsa04744 | Phototransduction | 9.21E-03 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Eprosartan | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Eprosartan | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Eprosartan | hsa04911 | Insulin secretion | 5.41E-03 | 3 | Q99941, P18848, Q13557 | CREBL1, ATF4, CAMK2D | More | | Eprosartan | hsa04912 | GnRH signaling pathway | 3.80E-04 | 6 | P17252, Q16539, Q9Y6R4, Q14643, P0DP23, P22694 | PRKCA, MAPK14, MAP3K4, ITPR1, CALM1, PRKACB | More | | Eprosartan | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Eprosartan | hsa04916 | Melanogenesis | 3.55E-02 | 3 | P0DP23, Q9UJU2, P17252 | CALM1, LEF1, PRKCA | More | | Eprosartan | hsa04918 | Thyroid hormone synthesis | 1.44E-02 | 3 | Q99941, P18848, P02768 | CREBL1, ATF4, ALB | More | | Eprosartan | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | Eprosartan | hsa04921 | Oxytocin signaling pathway | 4.19E-02 | 4 | P0DP23, P17252, Q16566, P63261 | CALM1, PRKCA, CAMK4, ACTG1 | More | | Eprosartan | hsa04922 | Glucagon signaling pathway | 4.18E-02 | 2 | P14618, P06737 | PKM2, PYGL | More | | Eprosartan | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Eprosartan | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | Eprosartan | hsa04925 | Aldosterone synthesis and secretion | 1.83E-05 | 9 | Q14643, Q99941, P18848, P0DP23, P17252, Q16566, Q13557, P20020, P23634 | ITPR1, CREBL1, ATF4, CALM1, PRKCA, CAMK4, CAMK2D, ATP2B1, ATP2B4 | More | | Eprosartan | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Eprosartan | hsa04927 | Cortisol synthesis and secretion | 2.92E-03 | 3 | Q99941, P18848, P22694 | CREBL1, ATF4, PRKACB | More | | Eprosartan | hsa04928 | Parathyroid hormone synthesis, secretion and action | 3.75E-02 | 5 | Q14643, P22694, P23771, P17252, P10415 | ITPR1, PRKACB, GATA3, PRKCA, BCL2 | More | | Eprosartan | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Eprosartan | hsa04932 | Non-alcoholic fatty liver disease | 2.05E-03 | 5 | O43521, P18848, O75460, P01584, P13073 | BCL2L11, ATF4, ERN1, IL1B, COX4I1 | More | | Eprosartan | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.36E-02 | 4 | Q13485, P10415, P49767, P17252 | SMAD4, BCL2, VEGFC, PRKCA | More | | Eprosartan | hsa04934 | Cushing syndrome | 8.89E-04 | 4 | Q99941, P18848, O15169, Q13557 | CREBL1, ATF4, AXIN1, CAMK2D | More | | Eprosartan | hsa04964 | Proximal tubule bicarbonate reclamation | 2.17E-03 | 1 | P00918 | CA2 | More | | Eprosartan | hsa04966 | Collecting duct acid secretion | 1.43E-04 | 3 | P02730, P00918, Q9Y666 | SLC4A1, CA2, SLC12A7 | More | | Eprosartan | hsa04970 | Salivary secretion | 4.63E-05 | 8 | P07550, P22694, Q14643, P20020, P23634, P17252, P0DP23, P49913 | ADRB2, PRKACB, ITPR1, ATP2B1, ATP2B4, PRKCA, CALM1, CAMP | More | | Eprosartan | hsa04971 | Gastric acid secretion | 4.76E-02 | 3 | P17252, P63261, P0DP23 | PRKCA, ACTG1, CALM1 | More | | Eprosartan | hsa04972 | Pancreatic secretion | 1.00E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | | Eprosartan | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Eprosartan | hsa04976 | Bile secretion | 2.44E-02 | 2 | P22694, P08183 | PRKACB, ABCB1 | More | | Eprosartan | hsa04978 | Mineral absorption | 3.94E-02 | 2 | P23634, Q9BXS9 | ATP2B4, SLC26A6 | More | | Eprosartan | hsa05010 | Alzheimer disease | 2.78E-02 | 6 | P13073, O75460, P0DP24, P01584, P18848, P05141 | COX4I1, ERN1, CALM2, IL1B, ATF4, SLC25A5 | More | | Eprosartan | hsa05012 | Parkinson disease | 3.44E-03 | 11 | P13073, P05141, P60604, O75460, P18848, P19174, P0DP23, P0DP24, Q71U36, Q13509, P68371 | COX4I1, SLC25A5, UBE2G2, ERN1, ATF4, PLCG1, CALM1, CALM2, TUBA1A, TUBB3, TUBB2C | More | | Eprosartan | hsa05014 | Amyotrophic lateral sclerosis | 4.31E-02 | 7 | O15399, P10415, Q13509, P68371, Q53GS7, P63261, Q9GZY0 | GRIN2D, BCL2, TUBB3, TUBB2C, GLE1, ACTG1, NXF2; NXF2B | More | | Eprosartan | hsa05016 | Huntington disease | 4.87E-02 | 5 | P13073, P24928, P62487, P05141, O75460 | COX4I1, POLR2A, POLR2G, SLC25A5, ERN1 | More | | Eprosartan | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.98E-02 | 7 | P13073, O75460, P18848, P05141, P20333, P01584, P0DP24 | COX4I1, ERN1, ATF4, SLC25A5, TNFRSF1B, IL1B, CALM2 | More | | Eprosartan | hsa05030 | Cocaine addiction | 4.36E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | | Eprosartan | hsa05031 | Amphetamine addiction | 3.32E-05 | 9 | O15399, P0DP23, Q16566, Q13557, P22694, Q99941, P18848, P17252, Q13547 | GRIN2D, CALM1, CAMK4, CAMK2D, PRKACB, CREBL1, ATF4, PRKCA, HDAC1 | More | | Eprosartan | hsa05032 | Morphine addiction | 2.18E-02 | 4 | P62873, P63218, P50151, Q13370 | GNB1, GNG5, GNG10, PDE3B | More | | Eprosartan | hsa05034 | Alcoholism | 3.90E-04 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Eprosartan | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 8.22E-06 | 9 | Q16539, P25963, Q13488, P09341, P19875, P19174, P25024, P25025, P07948 | MAPK14, NFKBIA, TCIRG1, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2, LYN | More | | Eprosartan | hsa05130 | Pathogenic Escherichia coli infection | 3.19E-02 | 6 | Q71U36, P16333, Q13509, P68371, Q14344, P25963 | TUBA1A, NCK1, TUBB3, TUBB2C, GNA13, NFKBIA | More | | Eprosartan | hsa05132 | Salmonella infection | 2.13E-05 | 17 | P51617, P25963, P08238, Q9UJU2, P63261, Q13546, Q13489, P10415, O75369, O60603, Q9BQS8, P51808, Q13561, Q71U36, Q13509, P68371, P49754 | IRAK1, NFKBIA, HSP90AB1, LEF1, ACTG1, RIPK1, BIRC3, BCL2, FLNB, TLR2, FYCO1, DYNLT3, DCTN2, TUBA1A, TUBB3, TUBB2C, VPS41 | More | | Eprosartan | hsa05133 | Pertussis | 3.22E-04 | 4 | P0DP23, P23528, P09871, P0C0L4 | CALM1, CFL1, C1S, C4A | More | | Eprosartan | hsa05134 | Legionellosis | 1.49E-03 | 5 | P25963, P11215, P11142, P09341, P19875 | NFKBIA, ITGAM, HSPA8, CXCL1, CXCL2 | More | | Eprosartan | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | | Eprosartan | hsa05140 | Leishmaniasis | 2.02E-03 | 8 | P14598, P11215, P42224, O60603, P25963, P49006, P51617, Q15080 | NCF1, ITGAM, STAT1, TLR2, NFKBIA, MARCKSL1, IRAK1, NCF4 | More | | Eprosartan | hsa05143 | African trypanosomiasis | 1.31E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | Eprosartan | hsa05144 | Malaria | 1.30E-05 | 7 | P60033, P69905, P68871, O60603, P01375, P35443, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, KLRK1 | More | | Eprosartan | hsa05146 | Amoebiasis | 3.23E-07 | 12 | Q13751, P09341, P19875, P14778, P27930, P01375, P42338, P11215, P05089, P30679, P22694, P12814 | LAMB3, CXCL1, CXCL2, IL1R1, IL1R2, TNF, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1 | More | | Eprosartan | hsa05150 | Staphylococcus aureus infection | 1.31E-02 | 2 | P0C0L4, P13646 | C4A, KRT13 | More | | Eprosartan | hsa05152 | Tuberculosis | 1.26E-02 | 8 | Q13488, O75015, P48382, O60603, P10415, P13765, Q9UDY8, Q16539 | TCIRG1, FCGR3B, RFX5, TLR2, BCL2, HLA-DOB, MALT1, MAPK14 | More | | Eprosartan | hsa05161 | Hepatitis B | 2.86E-02 | 3 | Q99941, P18848, P27348 | CREBL1, ATF4, YWHAQ | More | | Eprosartan | hsa05163 | Human cytomegalovirus infection | 1.72E-04 | 14 | P01375, P25963, P62873, P63218, P50151, P0DP23, Q14344, P49841, P14778, P25025, Q16539, O00463, P30101, P01568 | TNF, NFKBIA, GNB1, GNG5, GNG10, CALM1, GNA13, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5, PDIA3, IFNA21 | More | | Eprosartan | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 8.62E-05 | 10 | P01568, P42224, P25963, P62873, P63218, P50151, P19174, P07948, P04141, P0DP23 | IFNA21, STAT1, NFKBIA, GNB1, GNG5, GNG10, PLCG1, LYN, CSF2, CALM1 | More | | Eprosartan | hsa05168 | Herpes simplex virus 1 infection | 2.35E-03 | 15 | Q9UKJ0, P25963, P01568, Q9GZY0, P42224, Q07955, Q01130, Q13243, Q13489, P30101, Q13398, Q03923, O75820, Q9UDV6, P10415 | PILRB, NFKBIA, IFNA21, NXF2; NXF2B, STAT1, SFRS1, SFRS2, SFRS5, BIRC3, PDIA3, ZNF211, ZNF85, ZNF189, ZNF212, BCL2 | More | | Eprosartan | hsa05169 | Epstein-Barr virus infection | 2.15E-03 | 10 | P13765, Q92769, P04637, Q13546, P10415, P24522, O60603, P29728, P51617, P09693 | HLA-DOB, HDAC2, TP53, RIPK1, BCL2, GADD45A, TLR2, OAS2, IRAK1, CD3G | More | | Eprosartan | hsa05170 | Human immunodeficiency virus 1 infection | 2.55E-04 | 16 | P62873, P63218, P50151, P0DP23, P17252, Q13546, P30101, Q14643, P01568, P51617, P25963, O60603, P19174, P09693, P10415, Q9Y6Q5 | GNB1, GNG5, GNG10, CALM1, PRKCA, RIPK1, PDIA3, ITPR1, IFNA21, IRAK1, NFKBIA, TLR2, PLCG1, CD3G, BCL2, AP1M2 | More | | Eprosartan | hsa05171 | Coronavirus disease - COVID-19 | 1.51E-03 | 8 | P62753, P25398, P36578, P32969, P46776, P62899, P18077, P61927 | RPS6, RPS12, RPL4, RPL9, RPL27A, RPL31, RPL35A, RPL37 | More | | Eprosartan | hsa05200 | Pathways in cancer | 2.23E-05 | 30 | P08238, P42224, P25963, P19174, P04637, Q9UJU2, P17252, Q09472, P43246, P84022, Q13485, P20585, P14923, P10415, Q13489, Q13077, P49767, P25116, P62873, P63218, P50151, Q14344, O95267, P78417, P24522, O75293, P0DP23, P01568, P14784, P16871 | HSP90AB1, STAT1, NFKBIA, PLCG1, TP53, LEF1, PRKCA, EP300, MSH2, SMAD3, SMAD4, MSH3, JUP, BCL2, BIRC3, TRAF1, VEGFC, F2R, GNB1, GNG5, GNG10, GNA13, RASGRP1, GSTO1, GADD45A, GADD45B, CALM1, IFNA21, IL2RB, IL7R | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 1 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.783 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.818 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.869 | P32248 | CCR7 | C-C chemokine receptor type 7 | P04637 | TP53 | Cellular tumor antigen p53 | 0.77 | P46091 | GPR1 | Chemerin-like receptor 2 | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.736 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.813 | P46091 | GPR1 | Chemerin-like receptor 2 | P17252 | PRKCA | Protein kinase C alpha type | 0.741 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q09472 | EP300 | Histone acetyltransferase p300 | -0.791 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.816 | P46091 | GPR1 | Chemerin-like receptor 2 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.838 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | -0.77 | P46091 | GPR1 | Chemerin-like receptor 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.809 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P20585 | MSH3 | DNA mismatch repair protein Msh3 | 0.825 | P46091 | GPR1 | Chemerin-like receptor 2 | P14923 | JUP | Junction plakoglobin | 0.883 | P32248 | CCR7 | C-C chemokine receptor type 7 | P14923 | JUP | Junction plakoglobin | 0.711 | P46091 | GPR1 | Chemerin-like receptor 2 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.808 | P32248 | CCR7 | C-C chemokine receptor type 7 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.748 | P46091 | GPR1 | Chemerin-like receptor 2 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.759 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | 0.748 | P46091 | GPR1 | Chemerin-like receptor 2 | P49767 | VEGFC | Vascular endothelial growth factor C | 0.718 | P46091 | GPR1 | Chemerin-like receptor 2 | P25116 | F2R | Proteinase-activated receptor 1 | 0.76 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.82 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.703 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.704 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | -0.756 | P32248 | CCR7 | C-C chemokine receptor type 7 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | 0.792 | P46091 | GPR1 | Chemerin-like receptor 2 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | 0.738 | P32248 | CCR7 | C-C chemokine receptor type 7 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.862 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.742 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P0DP23 | CALM1 | Calmodulin-1 | 0.775 | P46091 | GPR1 | Chemerin-like receptor 2 | P0DP23 | CALM1 | Calmodulin-1 | -0.846 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P01568 | IFNA21 | Interferon alpha-21 | -0.733 | P46091 | GPR1 | Chemerin-like receptor 2 | P01568 | IFNA21 | Interferon alpha-21 | 0.724 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.717 | P32248 | CCR7 | C-C chemokine receptor type 7 | P16871 | IL7R | Interleukin-7 receptor subunit alpha | 0.743 |
| Eprosartan | hsa05202 | Transcriptional misregulation in cancer | 1.91E-04 | 16 | Q12778, Q15532, P41732, P14780, P27930, P14923, Q16548, Q13489, Q13077, O15550, P04637, P35226, P05164, P08246, Q9C0K0, P24522 | FOXO1, SS18, TSPAN7, MMP9, IL1R2, JUP, BCL2A1, BIRC3, TRAF1, UTX, TP53, BMI1, MPO, ELA2, BCL11B, GADD45A | More | | Eprosartan | hsa05203 | Viral carcinogenesis | 1.62E-04 | 7 | Q12933, Q99941, P18848, P27348, Q15283, P62807, O60814 | TRAF2, CREBL1, ATF4, YWHAQ, RASA2, HIST1H2BC, H2BC12 | More | | Eprosartan | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Eprosartan | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Eprosartan | hsa05210 | Colorectal cancer | 2.41E-02 | 4 | P10415, P04637, Q9UJU2, P24522 | BCL2, TP53, LEF1, GADD45A | More | | Eprosartan | hsa05212 | Pancreatic cancer | 1.05E-02 | 4 | P42224, P37173, P84022, O75293 | STAT1, TGFBR2, SMAD3, GADD45B | More | | Eprosartan | hsa05213 | Endometrial cancer | 1.91E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Eprosartan | hsa05214 | Glioma | 1.12E-04 | 7 | P0DP23, Q16566, P17252, P04637, P19174, P24522, O75293 | CALM1, CAMK4, PRKCA, TP53, PLCG1, GADD45A, GADD45B | More | | Eprosartan | hsa05215 | Prostate cancer | 1.94E-02 | 4 | P10415, Q9UJU2, Q09472, P04637 | BCL2, LEF1, EP300, TP53 | More | | Eprosartan | hsa05216 | Thyroid cancer | 2.42E-04 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Eprosartan | hsa05217 | Basal cell carcinoma | 1.56E-03 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Eprosartan | hsa05222 | Small cell lung cancer | 1.94E-02 | 4 | P10415, Q13077, P04637, P24522 | BCL2, TRAF1, TP53, GADD45A | More | | Eprosartan | hsa05224 | Breast cancer | 4.32E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Eprosartan | hsa05226 | Gastric cancer | 8.86E-03 | 5 | Q9UJU2, P04637, P24522, P14923, P10415 | LEF1, TP53, GADD45A, JUP, BCL2 | More | | Eprosartan | hsa05230 | Central carbon metabolism in cancer | 4.04E-02 | 2 | P07195, P04637 | LDHB, TP53 | More | | Eprosartan | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 8.27E-03 | 6 | P42338, P19174, P07766, P20963, P06239, Q04759 | PIK3CB, PLCG1, CD3E, CD247, LCK, PRKCQ | More | | Eprosartan | hsa05321 | Inflammatory bowel disease | 2.11E-03 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Eprosartan | hsa05322 | Systemic lupus erythematosus | 1.49E-05 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Eprosartan | hsa05332 | Graft-versus-host disease | 3.37E-04 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | Eprosartan | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 2.17E-03 | 1 | P54284 | CACNB3 | More | | Eprosartan | hsa05414 | Dilated cardiomyopathy | 4.55E-02 | 2 | P54284, P26678 | CACNB3, PLN | More | | Eprosartan | hsa05418 | Fluid shear stress and atherosclerosis | 2.49E-03 | 11 | Q16539, P78417, P10599, P14780, P01375, P63261, P10415, P14778, P27930, P0DP23, Q92974 | MAPK14, GSTO1, TXN, MMP9, TNF, ACTG1, BCL2, IL1R1, IL1R2, CALM1, ARHGEF2 | More | | |